Loading cancer entity…
Loading cancer entity…
Clinical trials
6,745 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,044)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03568656 | Study to Evaluate CCS1477 in Advanced Tumours | completed | Phase 1 / Phase 2 | 219 | CellCentric Ltd.INDUSTRY | 6 | Sep 25, 2026 | clinicaltrials |
| NCT05269485 | Hypofraction Radiotherapy for Locally Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 36 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05312840 |
| Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Sintilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer |
| completed |
| Phase 2 |
| 20 |
| People's Hospital of QuzhouOTHER |
| 1 |
| Sep 23, 2026 |
| clinicaltrials |
| NCT01350817 | Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer(TARSEQ) | completed | Phase 2 | 156 | University Hospital, LimogesOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05017025 | Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05882734 | Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) | completed | Phase 1 / Phase 2 | 61 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 8 | Sep 14, 2026 | clinicaltrials |
| NCT06501378 | Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis | completed | Phase 2 | 40 | Fudan UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04838548 | A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 87 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 98 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05299125 | Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations(AMIGO-1) | completed | Phase 2 | 54 | Latin American Cooperative Oncology GroupOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02434081 | NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma(NICOLAS) | completed | Phase 2 | 94 | ETOP IBCSG Partners FoundationNETWORK | 5 | Aug 24, 2026 | clinicaltrials |
| NCT03940703 | A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) | completed | Phase 2 | 140 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 17 | Aug 21, 2026 | clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT01159288 | Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes(CSET 1437) | completed | Phase 2 | 41 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT02994576 | Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer(PRINCEPS) | completed | Phase 2 | 60 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05348668 | Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer | completed | Phase 2 | 78 | Anhui Provincial HospitalOTHER_GOV | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05758116 | Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients | completed | Phase 2 | 5 | Peking University Cancer Hospital & InstituteOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT04769388 | Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib(FLAME) | completed | Phase 2 | 80 | Beijing Cancer Prevention & Treatment SocietyOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06249854 | Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 26 | Korea Institute of Oriental MedicineOTHER_GOV | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06139419 | The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC | completed | Phase 2 | 114 | Sun Yat-sen UniversityOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06532032 | A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer(swalloWTail) | completed | Phase 1 / Phase 2 | 12 | Janssen Research & Development, LLCINDUSTRY | 4 | Jul 31, 2026 | clinicaltrials |
| NCT02718066 | Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 96 | HUYABIO International, LLC.INDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05258279 | Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations | completed | Phase 2 | 30 | Juntendo UniversityOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT03581487 | Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT04563871 | Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)(BLOSSOM) | completed | Phase 2 | 73 | Sehhoon ParkOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT04776447 | Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)(APOLO) | completed | Phase 2 | 38 | Fundación GECPOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04702009 | Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 33 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05775289 | A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer | completed | Phase 2 | 182 | Hoffmann-La RocheINDUSTRY | 11 | Jul 20, 2026 | clinicaltrials |
| NCT03383302 | SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects(STILE) | completed | Phase 1 / Phase 2 | 36 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT01964157 | An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement | completed | Phase 2 | 32 | Yonsei UniversityOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT02186847 | Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer | completed | Phase 2 | 170 | NRG OncologyOTHER | 3 | Jul 13, 2026 | clinicaltrials |
| NCT04905316 | A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer(CHORUS) | completed | Phase 2 | 41 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04609566 | Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors | completed | Phase 2 | 161 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05375994 | Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients(RAMP204) | completed | Phase 1 / Phase 2 | 12 | Verastem, Inc.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT03801304 | Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer(VinMetAtezo) | completed | Phase 2 | 80 | University Hospital, BrestOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT01642251 | Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 156 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04084717 | Study of Crizotinib for ROS1 and MET Activated Lung Cancer | completed | Phase 2 | 33 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04318938 | Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping | completed | Phase 2 | 118 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04623775 | A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 468 | Bristol-Myers SquibbINDUSTRY | 19 | Jun 18, 2026 | clinicaltrials |
| NCT04181788 | Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies | completed | Phase 1 / Phase 2 | 155 | PfizerINDUSTRY | 6 | Jun 15, 2026 | clinicaltrials |
| NCT04262856 | Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer(ARC-7) | completed | Phase 2 | 151 | Arcus Biosciences, Inc.INDUSTRY | 7 | Jun 15, 2026 | clinicaltrials |
| NCT04205552 | Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients(NEOpredict) | completed | Phase 2 | 90 | University Hospital, EssenOTHER | 3 | Jun 11, 2026 | clinicaltrials |
| NCT05215067 | A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 44 | AkesoINDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT03516981 | A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) | completed | Phase 2 | 245 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Jun 8, 2026 | clinicaltrials |
| NCT04258033 | A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)(KUNPENG) | completed | Phase 2 | 145 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04619797 | A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer(SKYSCRAPER-06) | completed | Phase 2 / Phase 3 | 542 | Hoffmann-La RocheINDUSTRY | 21 | Jun 3, 2026 | clinicaltrials |
| NCT05546476 | Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15(PROACC-1) | completed | Phase 2 | 187 | PfizerINDUSTRY | 11 | Jun 3, 2026 | clinicaltrials |
| NCT05420220 | Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 95 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials